IL6 and non-small cell lung carcinoma: To further analyze whether apatinib inhibited NSCLC cells via STAT3 signaling, we treated A549 and H1299 cells with apatinb after pretreatment of 20 ng/mL interleukin-6 (IL-6), a major mediator of inflammation and activator of STAT3.